ArticleCureus2025
Multimodal Pain Management in Knee Osteoarthritis: A Comparative Study of Pregabalin and Duloxetine as Adjuncts to Naproxen.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis single-blinded, randomised, prospective study was carried out to investigate the effectiveness of a combination drug regimen including pregabalin and duloxetine as adjuncts to naproxen in pain management of patients with knee osteoarthritis (OA).
methodsOne hundred and five patients were inducted into the study following the inclusion and exclusion criteria. Using simple randomisation, patients were allocated into group A (naproxen only), group B (naproxen + duloxetine), and group C (naproxen + pregabalin). Visual analogue scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were used to measure pain severity, while secondary outcomes of sleep quality and depression were assessed by using the Pittsburgh Sleep Quality Index (PSQI) and Beck Depression Inventory (BDI) scale, respectively. Assessments were done at day 0, week 4, and week 12 in the study. Appropriate tests were utilised to analyse the data.
resultsMean pain scores at 12 weeks were significantly lower in group B (p=0.009 for VAS, p=0.002 for WOMAC) and group C (p=0.012 for VAS, p=0.005 for WOMAC), as compared to group A (naproxen only). Sleep quality (p=0.00) and depression scales (p=0.00) were also similarly improved in the combination drug regimen groups as compared to the naproxen-only group.
conclusionAddition of either duloxetine or pregabalin to the naproxen drug regimen may result in better management and improved quality of life in patients suffering from knee OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.